Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30070239 | 1.00 | L3MBTL1 (0.59) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL18893929 | 0.86 | HSD17B10 (0.60) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL11763299 | 0.83 | L3MBTL1 (0.52) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL27088455 | 0.82 | HSD17B10 (0.71) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL8149192 | 0.82 | ALDH1A1 (0.62) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL27155224 | 0.82 | ALDH1A1 (0.62) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL19259632 | 0.81 | KDM4E (0.51) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL3753324 | 0.80 | L3MBTL1 (0.64) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL423999 | 0.78 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL2262931 | 0.78 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-113801163-B | Organic arsenic-based II-type pyruvate kinase inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2025-03-04 | — | — | CN | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| EP-4434982-A1 | (S)-2-(2-METHYLAZETIDIN-1-YL)PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2024-09-25 | — | — | EP | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-117915918-A | Soluble adenylate cyclase (sAC) inhibitors and uses thereof | 康奈尔大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-4329762-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | Cornell University (US) | 2024-03-06 | — | — | EP | disclosed |
| US-5344843-A | Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders | HOFFMAN-LA ROCHE INC. (US) | 1994-09-06 | — | — | US | disclosed |
| WO-1994007846-A1 | RENIN INHIBITING N-(2-AMINO-2-OXOETHYL)BUTANEDIAMIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-04-14 | — | — | WO | disclosed |
| EP-0589445-A1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-03-30 | — | — | EP | disclosed |
| WO-1994002461-A1 | AZACYCLIC COMPOUNDS | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| EP-0580402-A2 | Aminediol protease inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-01-26 | — | — | EP | disclosed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
| US-5017576-A | Antianxiolytic, hypnotic, anticonvulsant, antiepileptic | RHONE-POULENC SANTE (FR) | 1991-05-21 | — | — | US | disclosed |
| US-4728647-A | Amides derived from quinoline, and anxiolytic compositions containing them | RHONE-POULENC SANTE (FR) | 1988-03-01 | — | — | US | disclosed |
| US-4530925-A | Aminocyclopentane esters and pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 1985-07-23 | — | — | US | disclosed |
| EP-0127930-A2 | Aminocyclopentane esters and their preparation and pharmaceutical formulation | GLAXO GROUP LIMITED (GB) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | L3MBTL1 4537/4885TSHR 1060/4885ALOX15 2640/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | L3MBTL1 691/4885TSHR 4714/4885ALOX15 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.